Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for Liver Fat and Metabolic Indices in Type 2 Diabetes with MASLD
IRCT20260602069614N1Phase 3Recruiting
- Sponsor
- Baqiyatallah University of Medical Sciences
- Start
- Jun 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3 trial of liraglutide in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Baqiyatallah University of Medical Sciences. Started Jun 2026; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20260602069614N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260602069614N1.